On Friday shares of Citizens Holding Company (NASDAQ:CIZN) closed at $18.38. Company’s sales growth for last 5 years was -4.10%. Citizens Holding Company (NASDAQ:CIZN) begin trading ex-dividend on March 12, 2015. A cash dividend payment of $0.23 per share is scheduled to be paid on March 31, 2015. Shareholders who purchased CIZN prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 4.55% increase over the same period a year ago.
Frontier Communications Corporation (NASDAQ:FTR) in last trading activity remains unchanged to close at $7.39. Company weekly performance is 1.51% while its quarterly performance stands at 14.40%. Frontier Communications Corporation (NASDAQ:FTR) is -11.38% away from its 52 week high. Frontier Communications Corporation (NASDAQ:FTR) scheduled to present at Goldman Sachs’ TMT Leveraged Finance Conference on Wednesday, March 11, 2015. John Gianukakis, Vice President and Treasurer, is scheduled to present at 8:50 a.m. Eastern Time on March 11th.
On last trading day Exa Corporation (NASDAQ:EXA) increased 8.77% to close at $11.41. Its volatility for the week is 5.53% while volatility for the month is 3.64%. EXA’s sales growth for past 5 years was 9.80% and its EPS growth for past 5 years was 41.80%. Exa Corporation (NASDAQ:EXA) monthly performance is 8.25%. Exa Corp (NYSE:EXA) issued its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.01) by $0.03.
Reis, Inc. (NASDAQ:REIS) has 21.20% insider ownership while its institutional ownership stands at 54.60%. In last trading activity company’s stock closed at $26.70. Reis, Inc. Reis, Inc. (NASDAQ:REIS) announced that it released its fourth quarter and annual 2014 results on the morning of Thursday, March 5, 2015.
On Friday shares of Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) closed at $0.69. Company’s sales growth for last 5 years was -26.80% . Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), announced preliminary topline results from a pilot clinical study which demonstrated bioequivalence of one formulation of NEXAFED (pseudoephedrine HCl) extended-release tablets to Sudafed® 12-Hour Tablets. NEXAFED extended-release tablets utilize Acura’s IMPEDE 2.0 enhanced methamphetamine-resistant technology. Acura intends to request a pre- IND meeting with the US Food and Drug Administration (FDA) to review this data and discuss a complete development program.